ebomi
Colour theme
Sign in
Insider · CIK 0001618442

Cormorant Global Healthcare Master Fund, LP

CIK 0001618442 Name as filed on the most recent filing

Filed as Cormorant Global Healthcare Master Fund, LP (59)

153 transaction lines · from 59 filings · filed 2016-11-07 to 2026-08-10 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2023-04-18 P, Open-market purchase Ambrx Biopharma Inc.AMAM 38,053,112, acquired Open Form 4 filing 0000929638-23-001211
2023-04-17 P, Open-market purchase Ambrx Biopharma Inc.AMAM 5,999,461, acquired Open Form 4 filing 0000929638-23-001185
2023-04-14 P, Open-market purchase Ambrx Biopharma Inc.AMAM 8,384,307, acquired Open Form 4 filing 0000929638-23-001185
2023-04-13 P, Open-market purchase Ambrx Biopharma Inc.AMAM 10,935,520, acquired Open Form 4 filing 0000929638-23-001185
2023-03-30 P, Open-market purchase Biomea Fusion, Inc.BMEA 12,000,000, acquired Open Form 4 filing 0000929638-23-001057
2023-03-16 P, Open-market purchase Ambrx Biopharma Inc.AMAM 5,074,250, acquired Open Form 4 filing 0000929638-23-000867
2023-03-15 P, Open-market purchase Ambrx Biopharma Inc.AMAM 2,648,875, acquired Open Form 4 filing 0000929638-23-000867
2023-03-14 P, Open-market purchase Ambrx Biopharma Inc.AMAM 2,488,275, acquired Open Form 4 filing 0000929638-23-000867
2022-12-13 P, Open-market purchase Erasca, Inc.ERAS 1,999,998, acquired Open Form 4 filing 0000929638-22-001904
2022-12-13 P, Open-market purchase Erasca, Inc.ERAS 1,999,998, acquired Open Form 4 filing 0000929638-22-001901
2021-10-25 P, Open-market purchase Ventyx Biosciences, Inc.VTYX 10,000,000, acquired Open Form 4 filing 0001567619-21-018789
2021-10-13 P, Open-market purchase Pyxis Oncology, Inc.PYXS 7,200,000, acquired Open Form 4 filing 0001567619-21-018355
2021-09-17 P, Open-market purchase Tyra Biosciences, Inc.TYRA 5,000,000, acquired Open Form 4 filing 0001567619-21-017389
2021-08-03 P, Open-market purchase Immuneering CorpIMRX 8,250,000, acquired Open Form 4 filing 0001567619-21-014499
2021-07-20 P, Open-market purchase Erasca, Inc.ERAS 15,200,000, acquired Open Form 4 filing 0001567619-21-013838
2021-07-02 P, Open-market purchase Aerovate Therapeutics, Inc.AVTE 7,000,000, acquired Open Form 4 filing 0001567619-21-013070
2021-06-29 P, Open-market purchase Elevation Oncology, Inc.ELEV 4,000,000, acquired Open Form 4 filing 0001567619-21-012841
2021-06-28 P, Open-market purchase Monte Rosa Therapeutics, Inc.GLUE 11,400,000, acquired Open Form 4 filing 0001567619-21-012781
2021-06-21 P, Open-market purchase Verve Therapeutics, Inc.VERV 5,225,000, acquired Open Form 4 filing 0001567619-21-012510
2021-04-27 P, Open-market purchase Rain Therapeutics Inc.RAIN 7,650,000, acquired Open Form 4 filing 0001567619-21-008744
2021-04-20 P, Open-market purchase Biomea Fusion, Inc.BMEA 15,300,000, acquired Open Form 4 filing 0001567619-21-008471
2021-03-30 P, Open-market purchase Design Therapeutics, Inc.DSGN 15,000,000, acquired Open Form 4 filing 0001567619-21-007374
2021-03-16 P, Open-market purchase Prometheus Biosciences, Inc.RXDX 7,125,000, acquired Open Form 4 filing 0001567619-21-006615
2020-12-18 P, Open-market purchase BioAtla, Inc.BCAB 14,400,000, acquired Open Form 4 filing 0001567619-20-021488
2020-11-23 P, Open-market purchase Olema Pharmaceuticals, Inc.OLMA 8,075,000, acquired Open Form 4 filing 0001567619-20-020222
2020-06-30 P, Open-market purchase Akouos, Inc.AKUS 4,930,000, acquired Open Form 4 filing 0001567619-20-012814
2020-06-16 P, Open-market purchase Avidity Biosciences, Inc.RNA 5,400,000, acquired Open Form 4 filing 0001567619-20-012364
2018-10-31 P, Open-market purchase Axonics Modulation Technologies, Inc.AXNX 1,999,995, acquired Open Form 4 filing 0001567619-18-005006
2018-06-25 P, Open-market purchase Kezar Life Sciences, Inc.KZR 3,750,000, acquired Open Form 4 filing 0001140361-18-030192
2018-05-29 P, Open-market purchase Kiniksa Pharmaceuticals, Ltd.KNSA 1,249,992, acquired Open Form 4 filing 0001140361-18-026543
2017-12-14 S, Open-market sale Proteostasis Therapeutics, Inc.PTI 2,461,164, acquired Open Form 4 filing 0001140361-17-046489
2017-11-13 P, Open-market purchase Apellis Pharmaceuticals, Inc.APLS 14,999,992, acquired Open Form 4 filing 0001140361-17-042815
2016-12-13 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 233,955, acquired Open Form 4 filing 0001140361-16-089670
2016-12-12 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 1,078,950, acquired Open Form 4 filing 0001140361-16-089670
2016-12-08 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 238,482, acquired Open Form 4 filing 0001140361-16-089278
2016-12-07 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 242,707, acquired Open Form 4 filing 0001140361-16-089278
2016-12-06 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 89,441, acquired Open Form 4 filing 0001140361-16-088915
2016-12-05 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 320,882, acquired Open Form 4 filing 0001140361-16-088915
2016-12-02 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 523,800, acquired Open Form 4 filing 0001140361-16-088915
2016-12-01 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 424,593, acquired Open Form 4 filing 0001140361-16-088417
2016-11-29 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 1,319,523, acquired Open Form 4 filing 0001140361-16-088417
2016-11-23 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 2 lines 2,052,506, acquired Open Form 4 filing 0001140361-16-087797
2016-11-22 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 769,817, acquired Open Form 4 filing 0001140361-16-087797
2016-11-21 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 1,302,622, acquired Open Form 4 filing 0001140361-16-087797
2016-11-14 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 109,016, acquired Open Form 4 filing 0001140361-16-086577
2016-11-11 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 242,975, acquired Open Form 4 filing 0001140361-16-086577
2016-11-10 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 2,398,587, acquired Open Form 4 filing 0001140361-16-086577
2016-11-09 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 117,121, acquired Open Form 4 filing 0001140361-16-086577
2016-11-07 P, Open-market purchase Proteostasis Therapeutics, Inc.PTI 2,012,616, acquired Open Form 4 filing 0001140361-16-085212

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. Cormorant Global Healthcare Master Fund, LP, insider transactions. Retrieved 2026-08-27 from https://ebomi.com/insider/0001618442

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.